Lawrence Elmer, MD, PhD joined the faculty of the University of Toledo College of Medicine in 1998 where he holds the position of Associate Professor of Neurology, Medical Director of the Center for Neurological Disorders, and Director of the Parkinson's Disease and Movement Disorder Program within the Department of Neurology. He serves on multiple national Parkinson's Disease advisory boards.
He is board certified by the American Board of Psychiatry and Neurology. He has been named on the list of "Best Doctors" since 2001.
Dr. Elmer's research is primarily focused on emerging pharmacologic treatments for Parkinson's disease. He has participated as a site investigator for the Parkinson Study Group for many years and is an ad hoc reviewer for journals such as Neurology, JNNP, and Movement Disorders.
Ted Rothstein, MD, is an Associate Professor of Neurology at George Washington University in Washington, DC. Dr. Rothstein received his BS degree from Union College and his medical degree from the Medical College of Virginia, in Richmond. He completed his residency in Neurology at the University of Washington.
He is the author of numerous peer-reviewed articles, abstracts and presentations, including "The Neglected Side of Parkinson's Disease" in American Scientist, Volume 96, 2008.
Andrew Siderowf, MD, is an Associate Professor of Neurology at the University of Pennsylvania Health System. Dr. Siderowf received his BA degree from Yale University and his medical degree from the Duke University School of Medicine in Durham, North Carolina. He completed residency in Neurology at the University of Pennsylvania. After a 2-year fellowship in experimental therapeutics (movement disorders) at Strong Memorial Hospital in Rochester, New York, Dr. Siderowf returned to Philadelphia to practice.
Dr. Siderowf is a member of the American Academy of Neurology (AAN), the Movement Disorders Society (MDS), and the Parkinson Study Group (PSG). He is medical director of the National Parkinson Foundation Center of Excellence at Pennsylvania Hospital.
Recognized as an expert on Parkinson’s Disease (PD) and movement disorders, Dr. Siderowf is the author of more than 70 peer-reviewed/invited articles and editorials on these and related subjects. His areas of interest include clinical trial design, cognitive impairment, and neuropsychiatric syndromes in neurodegenerative diseases. He has receives funding from the National Institutes of Health.
Matthew B. Stern, MD, is the Director of the Parkinson’s Disease and Movement Disorders Center and is the Parker Family Professor of Neurology at the University of Pennsylvania, Philadelphia. Dr Stern also codirects the Parkinson’s Disease Research, Education, and Clinical Center at the Philadelphia Veteran’s Hospital. Dr Stern received his medical degree from Duke University, Durham, North Carolina, and completed his neurology training at the University of Pennsylvania.
The Center at Penn is one of the largest of its type in the country and has a long track record of achievement in clinical trials and experimental therapeutics. Dr Stern has authored or co-authored numerous papers on Parkinson’s disease (PD) and edited or co-edited 8 books. He has served on the executive committee of the American Academy of Neurology’s Movement Disorders Section and is a member of the American Neurological Association. He has held several leadership positions in the international Movement Disorder Society and is currently Secretary-elect.
In addition to serving as institutional investigator for numerous clinical trials, Dr Stern has been the principal investigator or co-principal investigator of many studies related to PD. He serves on numerous consulting boards and has lectured throughout the world on PD and related disorders.
Mark F. Lew, MD, received his medical degree from George Washington University in Washington DC, where he also served his Internship in Internal Medicine. He completed his Residency in Neurology at Los Angeles County & University of Southern California Medical Center and his Fellowship in Movement Disorders at the University of Southern California in Los Angeles. He is a Fellow of the American Academy of Neurology and holds Board Certification from the American Board of Psychiatry and Neurology.
Dr Lew joined the faculty of the Keck School of Medicine of the University of Southern California in 1991, where he now holds the position of Professor of Neurology, Vice Chair of the department of Neurology and Director of the Division of Movement Disorders. At present, he is also the Director of the Movement Disorders Clinic at Los Angeles County+University of Southern California Medical Center.
Dr Lew is currently focusing on research in new pharmacologic treatments for Parkinson's disease. In addition, he is conducting clinical trials using new forms of botulinum toxin to treat focal dystonias. He is a Participating Scientist of both the Parkinson's Study Group and the Dystonia Study Group. Dr Lew is an active member of the Dystonia Medical Research Foundation, the Executive Committee of the Dystonia Study Group, the American Academy of Neurology, the Movement Disorder Society, the Medical Advisory Committee of the Musicians with Dystonia Program, the ACP Medicine Peer Review Board and a member of the WE MOVE education committee.
He is an ad hoc reviewer for Neurology, JNNP, and Movement Disorders. In addition, his own original clinical and research articles and abstracts have been published in such prestigious journals as JAMA, Science, Movement Disorders, Neurology, Annals of Neurology, American Journal of Psychiatry, Archives of Neurology, Journal of the American Geriatrics Society, Expert Reviews in Neurotherapeutics, Issues in Law and Medicine, Neurosurgery, Human Brain Mapping, American Journal of Human Genetics, Clinical Journal of Pain, Clinical Neuropharmacology, Neurologic Clinics, Neurobiology of Aging, Current Medical Research and Opinion, Pharmacotherapy, Journal of Neurological Sciences, and Expert Review of Neurotherapeutics.
Robert Hauser, MD, MBA, is Professor of Neurology, Molecular Pharmacology and Physiology at the University of South Florida. He is Director of the Parkinson’s Disease and Movement Disorders Center, and Director of the Clinical Signature Interdisciplinary Program in Neuroscience. Dr. Hauser’s research focuses on the development of new treatments for Parkinson’s disease and other movement disorders. His expertise includes clinical trial design and execution. Dr. Hauser has authored or co-authored more than 150 peer-reviewed publications and has lectured frequently at scientific meetings around the world. He is a Past Chairman of the Interventional Neurology Section of the American Academy of Neurology, has served on the executive committee of the Parkinson Study Group and is currently a steering committee member for the NIH Neuroprotective Exploratory Trials (NET-PD) program.
Karl Kieburtz, MD, is Professor of Neurology, Community & Preventive Medicine, Environmental Medicine and the Director of the Center for Human Experimental Therapeutics. He is helping to develop a T1 Key Function for the CTSI. His primary clinical and research interests are neurodegenerative diseases affecting the basal ganglia, particularly Parkinson disease, Huntington disease, and HIV related neurologic disorders. He is the principal investigator for the NINDS sponsored trials of neuroprotective agents for PD (NET-PD) and currently chairs the Executive Committee of the Parkinson Study Group. He also directs the Coordination Center for other NIH and foundation supported multi-center academic research consortia.